SAN MATEO, Calif., June 29, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today announced that it has been notified by The NASDAQ Stock Market (NASDAQ) that trading in the Company’s securities will be suspended on NASDAQ effective with the open of trading on Friday, June 29, 2012. On that same date, the Company’s common stock will be eligible to trade on the Over the Counter Bulletin Board (OTCBB), a market tier for OTC-traded companies that are registered and current in their reporting obligations with the Securities and Exchange Commission. The Company’s trading symbol will remain NGSX.
